Quibim

Transforming imaging data into actionable predictions



01

DATA AND IMAGE HARMONIZATION:

A solution for imaging harmonization, ensuring standardized image quality irrespective of the acquisition protocol or scanner used.



02

ORGAN/LESION SEGMENTATION:

A tissue-agnostic methodology for model development applicable to various imaging modalities, anatomical regions, and clinical conditions.



03

IMAGING PREDICTIVE BIOMARKERS EXTRACTION:

Feature-based models for the extraction of thousands of tissue-related variables by using different computational models. (e.g. radiomics and deep features).

04

IMAGING PANEL REPORT:

We aim to optimize drug development and treatment programs and improve patient outcomes through precision medicine.

Achieving success through data, technology and partnerships

Our **tissue-agnostic platform leverages imaging data to enhance patient outcomes.** We use AI to extract insights from medical images and develop **unique quantitative imaging biomarkers**. With access to over 100M imaging registries from 50,000+ oncology patients, we're **leading RWE studies and collaborating with biopharma companies** to explore disease mechanisms, expedite drug development, and monitor treatment progress. Our advanced procedure not only normalizes the quality of MRI, CT, PET, SPECT, x-ray, and ultrasound images but also detects tissues, organs, and anomalies within these uniform images. **This method ensures the selection of the most robust radiomic features for developing AI-based predictive models.**

Quibim

Lung Cancer
85+ sites | 13150+ imaging exams

Rectal Cancer
10+ sites | 12000+ imaging exams

Prostate Cancer
20+ sites | 30150+ imaging exams

Pediatric Cancer
10+ sites | 3100+ imaging exams

Breast Cancer and Gynecological
30+ sites | 12000+ imaging exams

Other Cancers in the pipeline
Melanoma | HNSCC | HCC | DLBCL | Pancreatic | Glioblastoma

Case study: Prediction of treatment response to immunotherapy in NSCLC

SCENARIO:

A biopharma company was interested in using an AI model to predict NSCLC patient responses to immune checkpoint inhibitors using diagnostic CT imaging exams. The model could improve clinical trial enrollment and patient stratification, as well as serve as a diagnostic tool.

RESULTS:

The biopharma partner engaged in a long value-based strategic collaboration with us to design and create an AI algorithm based on radiomics, deep features, and deep learning techniques, which predicts whether the patient will respond to immunotherapy in 80% of cases.

OUTCOME:

The biopharma partner aims to license our AI model to enhance patient selection in future immunotherapy and NSCLC clinical studies. Our tools could be seamlessly integrated with hospital systems for automated CT scan analysis.







- Radiomic features
- Deep features
- Deep learning

Image and feature domain harmonization, adaptation domain and bias reduction.

- Progression-free survival (PFS)
- Overall survival (OS)
- Overall response rate (ORR)
- Early progression